Key result
Gastric bypass surgery in morbidly obese patients was associated with massive weight loss, improved insulin sensitivity, and reduced inflammatory markers, increasing endocannabinoid levels.
Why the study?
Does gastric bypass surgery improve metabolic and inflammatory profiles in morbidly obese patients?
Cohort (n=31)
No
Does gastric bypass surgery improve metabolic and inflammatory profiles in morbidly obese patients?
Gastric bypass surgery in morbidly obese patients improves metabolic and inflammatory profiles, potentially mediated by increased endocannabinoid levels in adipose tissue.
Answers are grounded in this paper and cite their sources.
May support metabolic benefits of gastric bypass in obesity; leaves open causal role of endocannabinoids pending randomized data.
Paradoxically, morbid obesity was suggested to protect from cardiovascular co-morbidities as compared to overweight/obese patients. We hypothesise that this paradox could be inferred to modulation of the "endocannabinoid" system on systemic and subcutaneous adipose tissue (SAT) inflammation. We designed a translational project including clinical and in vitro studies at Geneva University Hospital. Morbid obese subjects (n=11) were submitted to gastric bypass surgery (GBS) and followed up for one year (post-GBS). Insulin resistance and circulating and SAT levels of endocannabinoids, adipocytokines and CC chemokines were assessed pre- and post-GBS and compared to a control group of normal and overweight subjects (CTL) (n=20). In vitro cultures with 3T3-L1 adipocytes were used to validate findings from clinical results. Morbid obese subjects had baseline lower insulin sensitivity and higher hs-CRP, leptin, CCL5 and anandamide (AEA) levels as compared to CTL. GBS induced a massive weight and fat mass loss, improved insulin sensitivity and lipid profile, decreased C-reactive protein, leptin, and CCL2 levels. In SAT, increased expression of resistin, CCL2, CCL5 and tumour necrosis factor and reduced MGLL were shown in morbid obese patients pre-GBS when compared to CTL. GBS increased all endocannabinoids and reduced adipocytokines and CC chemokines. In morbid obese SAT, inverse correlations independent of body mass index were shown between palmitoylethanolamide (PEA) and N-oleoylethanolamide (OEA) levels and inflammatory molecules. In vitro, OEA inhibited CCL2 secretion from adipocytes via ERK1/2 activation. In conclusion, GBS was associated with relevant clinical, metabolic and inflammatory improvements, increasing endocannabinoid levels in SAT. OEA directly reduced CCL2 secretion via ERK1/2 activation in adipocytes.
No takes yet. Share an insight, caveat, or question.
Quercioli et al. (2014) conducted a cohort in Morbid obesity (n=31). Gastric bypass surgery vs. Normal and overweight subjects was evaluated on Insulin resistance and circulating and subcutaneous adipose tissue levels of endocannabinoids, adipocytokines and CC chemokines. Gastric bypass surgery in morbidly obese patients was associated with massive weight loss, improved insulin sensitivity, and reduced inflammatory markers, increasing endocannabinoid levels.
Synapse has enriched 10 related papers. Consider them for comparative context: